News

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Former Google CEO warns ‘AI could surpass human intelligence in next few years’; what is artificial superintelligence and why it matters
Former Google CEO Eric Schmidt warns that Artificial Superintelligence (ASI), surpassing human intelligence, is imminent. He ...
GEN - Genetic Engineering and Biotechnology News4d
Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery
While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is…'
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...
The Chosun Ilbo on MSN6d
South Korea ramps up AI-driven drug development amid global investment surge
The administration of South Korean President Lee Jae-myung, which has positioned itself as an “artificial intelligence ...
Oneindia4d
Artificial Superintelligence Could Outthink All Humans Combined, Warns Former Google CEO
Eric Schmidt warns society is unprepared for the rapid arrival of Artificial Superintelligence. He highlights significant ...